205 related articles for article (PubMed ID: 11030470)
21. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
Ikenoue T; Kondo N
Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747
[TBL] [Abstract][Full Text] [Related]
22. Nateglinide in combination with metformin in Chinese patients with type 2 diabetes mellitus: a post-marketing surveillance study.
Yang JK; Wang L;
Clin Drug Investig; 2013 Mar; 33(3):185-91. PubMed ID: 23338975
[TBL] [Abstract][Full Text] [Related]
23. Nateglinide (Starlix): update on a new antidiabetic agent.
Phillips LS; Dunning BE
Int J Clin Pract; 2003; 57(6):535-41. PubMed ID: 12918894
[TBL] [Abstract][Full Text] [Related]
24. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.
Karara AH; Dunning BE; McLeod JF
J Clin Pharmacol; 1999 Feb; 39(2):172-9. PubMed ID: 11563410
[TBL] [Abstract][Full Text] [Related]
25. Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes.
Lindsay JR; McKillop AM; Mooney MH; O'Harte FP; Flatt PR; Bell PM
Diabetes Res Clin Pract; 2003 Sep; 61(3):167-73. PubMed ID: 12965106
[TBL] [Abstract][Full Text] [Related]
26. Restoring post-prandial insulin release in type 2 diabetes.
Andrews J
Hosp Med; 2002 Feb; 63(2):95-8. PubMed ID: 11902096
[TBL] [Abstract][Full Text] [Related]
27. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
Iwase M; Nakamura U; Uchizono Y; Nohara S; Sasaki N; Sonoki K; Iida M
Eur J Pharmacol; 2005 Aug; 518(2-3):243-50. PubMed ID: 16023099
[TBL] [Abstract][Full Text] [Related]
28. [Progress in therapy for diabetes mellitus--insulin-secretion inducing oral hypoglycemic agents].
Nagashima K; Inagaki N
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):737-41. PubMed ID: 19472523
[No Abstract] [Full Text] [Related]
29. Nateglinide.
Halas CJ
Am J Health Syst Pharm; 2001 Jul; 58(13):1200-5. PubMed ID: 11449877
[TBL] [Abstract][Full Text] [Related]
30. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.
Marre M; Van Gaal L; Usadel KH; Ball M; Whatmough I; Guitard C
Diabetes Obes Metab; 2002 May; 4(3):177-86. PubMed ID: 12047396
[TBL] [Abstract][Full Text] [Related]
31. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
Pratley RE; Foley JE; Dunning BE
Curr Pharm Des; 2001 Sep; 7(14):1375-97. PubMed ID: 11472274
[TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamics, insulinotropic action and hypoglycemic effect of nateglinide and glibenclamide in normal and diabetic rats.
Courtois P; Jijakli H; Ladriere L; Oguzhan B; Sener A; Malaisse WJ
Int J Mol Med; 2003 Jan; 11(1):105-9. PubMed ID: 12469228
[TBL] [Abstract][Full Text] [Related]
33. Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets.
Makino C; Ninomiya N; Sakai H; Orita H; Okano A; Yabuki A
Chem Pharm Bull (Tokyo); 2006 Apr; 54(4):409-14. PubMed ID: 16595936
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure.
Inoue T; Shibahara N; Miyagawa K; Itahana R; Izumi M; Nakanishi T; Takamitsu Y
Clin Nephrol; 2003 Aug; 60(2):90-5. PubMed ID: 12940610
[TBL] [Abstract][Full Text] [Related]
35. Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.
González-Ortiz M; Hernández-Salazar E; Martínez-Abundis E
J Diabetes Complications; 2005; 19(6):356-60. PubMed ID: 16260353
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of nateglinide in the treatment of type II diabetes mellitus.
Chandrasekharan S; Rao PP; Jayaram S; Jain SD; Ganesan R; Desai A
J Indian Med Assoc; 2002 Jul; 100(7):467-8. PubMed ID: 12674176
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
Horton ES; Foley JE; Shen SG; Baron MA
Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
[TBL] [Abstract][Full Text] [Related]
38. Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.
Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
Intern Med; 2007; 46(22):1837-46. PubMed ID: 18025765
[TBL] [Abstract][Full Text] [Related]
39. Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide.
Mari A; Gastaldelli A; Foley JE; Pratley RE; Ferrannini E
Diabetes Care; 2005 May; 28(5):1132-8. PubMed ID: 15855578
[TBL] [Abstract][Full Text] [Related]
40. Somatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreas.
Fujitani S; Ikenoue T; Akiyoshi M; Maki T; Yada T
Metabolism; 1996 Feb; 45(2):184-9. PubMed ID: 8596487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
